U.S. Cell Therapy Market Size & Outlook, 2023-2030
U.S. Cell Therapy Market, 2018-2030 (US$M)
Global Market
Related Markets
U.S. cell therapy market highlights
- The U.S. cell therapy market generated a revenue of USD 2,662.6 million in 2023 and is expected to reach USD 10,342.9 million by 2030.
- The U.S. market is expected to grow at a CAGR of 21.4% from 2024 to 2030.
- In terms of segment, autologous therapies was the largest revenue generating therapy type in 2023.
- Allogeneic Therapies is the most lucrative therapy type segment registering the fastest growth during the forecast period.
Cell therapy market data book summary
| Market revenue in 2023 | USD 2,662.6 million |
| Market revenue in 2030 | USD 10,342.9 million |
| Growth rate | 21.4% (CAGR from 2023 to 2030) |
| Largest segment | Autologous therapies |
| Fastest growing segment | Allogeneic Therapies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Allogeneic Therapies, Autologous Therapies |
| Key market players worldwide | Novartis AG ADR, Gilead Sciences Inc, Bristol-Myers Squibb Co, Johnson & Johnson, JCR Pharmaceuticals Co Ltd, JW (Cayman) Therapeutics Co Ltd Ordinary Shares, Atara Biotherapeutics Inc, Medipost, Beiersdorf AG, Nkarta Inc Ordinary Shares |
Other key industry trends
- In terms of revenue, U.S. accounted for 56.2% of the global cell therapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. cell therapy market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 576.5 million by 2030.
The U.S. Food and Drug Administration (FDA) is the main regulatory body in the country. The U.S. regulatory authorities categorize gene, cell, and tissue-engineered products as advanced therapies. Cellular and tissue-based therapies are regulated by the Center for Biologics Evaluation and Research (CBER), which is a part of the Food and Drug Authority.
Cellular therapy products incorporate cellular immunotherapies and different types of allogeneic & autologous cells for certain therapeutic indications, including adult & embryonic stem cells and hematopoietic stem cells. The CBER considers the Federal Food, Drug, and Cosmetic Act and the Public Health Service for regulating cellular therapy products that are either commercialized or in the pipeline.
Cellular therapies are further classified as regulated under Section 361 and Section 351 according to the Public Health Service Act. Similar to other biological drugs, cellular therapy products under section 351 have to receive premarket approval.
Key Regions:U.S., UK, Japan, South Korea, Germany
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Cell Therapy Market Scope
Cell Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Beiersdorf AG | View profile | 21,958 | Unnastrasse 48, Hamburg, Germany, 22529 | www.beiersdorf.com |
| Gilead Sciences Inc | View profile | 18,000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | www.gilead.com |
| JCR Pharmaceuticals Co Ltd | View profile | 932 | 3-19 Kasuga-cho, Ashiya, Hyogo, Japan, 659-0021 | www.jcrpharm.co.jp |
| Medipost | View profile | 51-100 | Seongnam, Kyonggi-do, South Korea, Asia | www.medi-post.com/ |
| JW (Cayman) Therapeutics Co Ltd Ordinary Shares | View profile | 398 | No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, China, People's Republic of | www.jwtherapeutics.com |
| Atara Biotherapeutics Inc | View profile | 173 | 2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, United States, 91320 | www.atarabio.com |
| Nkarta Inc Ordinary Shares | View profile | 150 | 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080 | www.nkartatx.com |
U.S. Cell Therapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell Therapy Market Outlook will help companies and investors design strategic landscapes.
Autologous Therapies was the largest segment with a revenue share of 90.66% in 2023.
Horizon Databook has segmented the U.S. cell therapy market based on allogeneic therapies, autologous therapies covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. Food and Drug Administration (FDA) is the main regulatory body in the country. The U.S. regulatory authorities categorize gene, cell, and tissue-engineered products as advanced therapies. Cellular and tissue-based therapies are regulated by the Center for Biologics Evaluation and Research (CBER), which is a part of the Food and Drug Authority.
Cellular therapy products incorporate cellular immunotherapies and different types of allogeneic & autologous cells for certain therapeutic indications, including adult & embryonic stem cells and hematopoietic stem cells. The CBER considers the Federal Food, Drug, and Cosmetic Act and the Public Health Service for regulating cellular therapy products that are either commercialized or in the pipeline.
Cellular therapies are further classified as regulated under Section 361 and Section 351 according to the Public Health Service Act. Similar to other biological drugs, cellular therapy products under section 351 have to receive premarket approval.
- U.S. Cell Therapy Market Therapy Type Outlook (Revenue, USD Million , 2018-2030)
- Allogeneic Therapies
- Autologous Therapies
- U.S. Cell Therapy Market Therapeutic Area Outlook (Revenue, USD Million , 2018-2030)
- Oncology
- Cardiovascular Disease (CVD)
- Musculoskeletal Disorders
- Dermatology
- Others
Reasons to subscribe to Cell Therapy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell Therapy Market Outlook databook
- Our clientele includes a mix of Cell Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Cell Therapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Cell Therapy Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
U.S. Cell Therapy Market, 2018-2030 (US$M)
U.S. cell therapy market statistics, by therapy type, 2018-2030 (US$M)
